|
시장보고서
상품코드
2102159
퍼투주맙 시장 규모, 점유율, 성장 분석 : 적응증별, 치료법별, 제형별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Pertuzumab Market Size, Share, and Growth Analysis, By Indication (HER2-Positive Breast Cancer, Early Breast Cancer), By Therapy Type, By Dosage Form, By End User, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 퍼투주맙 시장 규모는 2024년에 43억 달러로 평가되었으며, 2025년 45억 4,000만 달러에서 2033년까지 69억 7,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 5.5%로 성장할 것으로 전망됩니다.
HER2의 이량체화를 억제하는 단일클론 항체인 퍼투주맙은 지속적으로 확대되고 있는 HER2 양성 암 치료 시장의 핵심을 이루고 있습니다. 한때 틈새 치료법이었던 이 치료 옵션은 전이성 유방암에서의 효능을 바탕으로 1차 표준 치료법으로 자리 잡았으며, 막대한 수익을 창출하고 있습니다. 이 시장의 중요성은 유방암과 위암을 비롯한 다양한 암에서 HER2 증폭 종양이 널리 관찰된다는 점에서도 입증되고 있습니다. 주목할 만한 임상시험을 통해 치료 성과가 현저히 개선된 사실이 밝혀지면서, 의료 시스템 전반에 걸친 광범위한 도입이 진행되고 있습니다. 유방암 이외의 적응증 확대는 수요를 더욱 다각화시키고 있으며, 제약 기업의 투자와 보험 급여 절차 효율화를 위한 노력을 촉진하고 있습니다. 개발 및 시장 분석 분야의 AI 발전에 힘입은 바이오시밀러의 부상은, 특히 저소득 지역에서의 접근성을 향상시켜 수익 성장을 가속화하는 동시에 종양학 분야에서 퍼투주맙의 입지를 공고히 하고 있습니다.
세계 퍼투주맙 시장의 성장요인
표적 치료에 대한 인식이 높아짐에 따라, 의료 종사자들이 환자의 예후를 개선하는 정밀 의학에 점점 더 집중하게 되면서 퍼투주맙에 대한 수요가 크게 증가하고 있습니다. 퍼투주맙을 기존 치료 프로토콜에 통합함으로써, 의료 제공자들은 치료가 어려운 유방암 아형을 가진 환자들의 요구에 효과적으로 대응하고 있으며, 그 결과 이 약물의 효능에 대한 신뢰가 더욱 강화되고 있습니다. 이러한 통합으로 인해 병원 및 종양 클리닉은 퍼투주맙을 약제 목록에 추가하게 되었으며, 다양한 의료 환경에서 시장 접근성이 확대되어 지속적인 성장이 촉진되고 있습니다. 또한, 지속적인 교육 활동과 신뢰도 높은 학술 논문을 통해 임상 현장에서의 신뢰도가 높아지면서, 다학제 의료팀 내에서의 추가 도입이 촉진되고 있습니다.
세계 퍼투주맙 시장의 제약요인
퍼투주맙의 높은 비용은, 특히 재정 자원이 제한된 지역에서, 의료 시스템에 있어 중대한 보험 급여상의 과제가 되고 있습니다. 보험사는 약제 목록 등재를 정당화하기 위해 종합적인 경제성 평가를 빈번히 요구하고 있으며, 이는 환자의 약물 접근 지연이나 제한으로 이어질 가능성이 있습니다. 그 결과, 퍼투주맙의 임상적 유효성이 입증되었음에도 불구하고, 의료 제공자는 더 저렴한 대체 약물을 선택할 가능성이 있습니다. 이러한 재정적 장벽은 시장 성장을 저해할 뿐만 아니라, 제조사와 보험사 간의 협상을 격화시켜 치료 기관에서의 광범위한 도입을 제한하는 보험 적용 정책으로 이어질 수 있습니다. 이러한 상황에서 의료 기관은 환자를 위해 ‘자비적 사용(Compassionate Use)’이라는 선택지를 고려할 수밖에 없을지도 모릅니다.
세계 퍼투주맙 시장 동향
세계 퍼투주맙 시장은 종양학 분야에서 새로운 병용요법의 부상이라는 추세에 힘입어 눈부신 성장을 이루고 있습니다. 임상의들은 상호 보완적인 신호 전달 경로를 표적으로 하는 다제 병용요법에 퍼투주맙을 포함시키는 사례가 증가하고 있으며, 이를 통해 HER2 양성 악성 종양 환자의 치료 반응을 높이고 생존율을 향상시키는 것을 목표로 하고 있습니다. 이러한 맞춤형 의료로의 전환은 치료 저항성을 극복하고 관해 지속 기간을 연장하기 위해 페르츠주맙과 함께 신규 항체, 면역관문억제제 및 표적 지향성 저분자 약물을 전략적으로 병용하는 추세에 반영되어 있습니다. 이러한 병용 전략이 발전함에 따라, 퍼츠주맙은 현대 치료 알고리즘에서 필수적인 요소로서의 위상을 확립하고 있으며, 궁극적으로 환자의 예후를 개선함으로써 세계 시장에서 그 중요성을 확고히 하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 퍼투주맙 시장 규모 : 적응증별
세계의 퍼투주맙 시장 규모 : 요법 유형별
세계의 퍼투주맙 시장 규모 : 제형별
세계의 퍼투주맙 시장 규모 : 최종사용자별
세계의 퍼투주맙 시장 규모 : 유통 채널별
세계의 퍼투주맙 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.03Global Pertuzumab Market size was valued at USD 4.3 Billion in 2024 and is poised to grow from USD 4.54 Billion in 2025 to USD 6.97 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).
Pertuzumab, a monoclonal antibody that inhibits HER2 dimerization, is central to the growing market for HER2-positive cancer treatments. This therapeutic option, once niche, has established itself as a frontline standard due to its efficacy in metastatic breast cancer, generating substantial revenues. The relevance of this market is underscored by the prevalence of HER2-amplified tumors in various cancers, including breast and gastric types. Notable clinical trials have highlighted significant improvements in treatment outcomes, driving widespread integration into healthcare systems. Expanding indications beyond breast cancer further diversify demand, prompting pharmaceutical investments and efforts to streamline reimbursement pathways. The rise of biosimilars, supported by AI advancements in development and market analysis, enhances accessibility, particularly in lower-income regions, thereby accelerating revenue growth and solidifying pertuzumab's role in oncology.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pertuzumab market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Pertuzumab Market Segments Analysis
Global pertuzumab market is segmented by indication, therapy type, dosage form, end user, distribution channel and region. Based on indication, the market is segmented into HER2-Positive Breast Cancer, Early Breast Cancer, Metastatic Breast Cancer, Neoadjuvant Therapy and Others. Based on therapy type, the market is segmented into Combination with Trastuzumab & Chemotherapy, Combination with Trastuzumab, Combination with Other HER2-Targeted Therapies, Monotherapy (Clinical Research) and Others. Based on dosage form, the market is segmented into Intravenous Infusion, Subcutaneous Fixed-Dose Combination and Others. Based on end user, the market is segmented into Hospitals, Oncology Centers, Specialty Clinics, Academic & Research Institutes and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies, Direct Procurement and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Pertuzumab Market
The increasing recognition of targeted therapies significantly boosts the demand for pertuzumab, as healthcare professionals increasingly focus on precision treatments that enhance patient outcomes. By incorporating pertuzumab into existing treatment protocols, providers effectively meet the needs of patients with challenging breast cancer subtypes, thereby reinforcing trust in the drug's effectiveness. This integration motivates hospitals and oncology clinics to include pertuzumab in their medication lists, facilitating greater market access and ongoing growth across various healthcare environments. Moreover, continuous educational efforts and reputable publications bolster clinical confidence, encouraging further adoption among interdisciplinary medical teams.
Restraints in the Global Pertuzumab Market
The elevated cost of pertuzumab poses significant reimbursement challenges for healthcare systems, especially in areas with limited financial resources. Payers frequently demand comprehensive economic evaluations to justify formulary inclusion, which can lead to delays or restrictions in patient access to the medication. As a result, healthcare providers may choose more affordable alternatives, despite pertuzumab's proven clinical effectiveness. This financial obstacle not only stifles market growth but also heightens negotiations between manufacturers and insurers, potentially leading to restrictive coverage policies that limit wider acceptance in treatment facilities. This scenario may force institutions to explore compassionate use options for their patients.
Market Trends of the Global Pertuzumab Market
The global pertuzumab market is experiencing significant growth driven by the rising trend of emerging combination therapies in oncology. Clinicians are increasingly incorporating pertuzumab into multi-agent treatment regimens that target complementary pathways, thereby aiming to enhance therapeutic responses and improve survival rates in patients with HER2-positive malignancies. This shift toward personalized medicine is reflected in the strategic use of novel antibodies, immune checkpoint inhibitors, and targeted small molecules alongside pertuzumab, which aims to overcome treatment resistance and increase remission durability. As these combination strategies evolve, pertuzumab is positioned as a vital component within modern treatment algorithms, ultimately improving patient outcomes and solidifying its relevance across global markets.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Pertuzumab Market Size by Indication & CAGR (2026-2033)
- Market Overview
- HER2-Positive Breast Cancer
- Early Breast Cancer
- Metastatic Breast Cancer
- Neoadjuvant Therapy
- Others
Global Pertuzumab Market Size by Therapy Type & CAGR (2026-2033)
- Market Overview
- Combination with Trastuzumab & Chemotherapy
- Combination with Trastuzumab
- Combination with Other HER2-Targeted Therapies
- Monotherapy (Clinical Research)
- Others
Global Pertuzumab Market Size by Dosage Form & CAGR (2026-2033)
- Market Overview
- Intravenous Infusion
- Subcutaneous Fixed-Dose Combination
- Others
Global Pertuzumab Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Oncology Centers
- Specialty Clinics
- Academic & Research Institutes
- Others
Global Pertuzumab Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Specialty Pharmacies
- Direct Procurement
- Others
Global Pertuzumab Market Size & CAGR (2026-2033)
- North America (Indication, Therapy Type, Dosage Form, End User, Distribution Channel)
- US
- Canada
- Europe (Indication, Therapy Type, Dosage Form, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Indication, Therapy Type, Dosage Form, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Indication, Therapy Type, Dosage Form, End User, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Indication, Therapy Type, Dosage Form, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Bioepis Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Celltrion, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz Group AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocon Biologics Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Shanghai Henlius Biotech, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Accord Healthcare Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BeiGene, Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intas Pharmaceuticals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alvotech S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
